Management of Post-Transplant Membranous Nephropathy

Diagnostic Considerations

Negative PLA2R serum levels in post-transplant patients with membranous nephropathy (MN) suggests a secondary form of MN, potentially related to the immunosuppressive regimen 1
Tacrolimus and other calcineurin inhibitors (CNIs) can contribute to nephrotoxicity and may exacerbate proteinuria in patients with MN 2, 3

Reducing tacrolimus dosage to target lower trough levels (4-6 ng/ml) can minimize nephrotoxicity while maintaining adequate immunosuppression, as recommended by the American Journal of Kidney Diseases 4, 5
Continuing mycophenolate mofetil (MMF) at current dosage has minimal impact on renal function, according to the Journal of Hepatology and American Journal of Transplantation 3, 6
Maintaining steroid therapy but considering gradual dose reduction if clinically appropriate is suggested by Gut 7
Initiating ACE inhibitor or ARB therapy can reduce proteinuria, unless contraindicated, as recommended by the American Journal of Kidney Diseases 1
Monitoring blood pressure, serum creatinine, and potassium levels closely after starting these medications is advised by the American Journal of Transplantation 6

If proteinuria persists, considering further reduction of tacrolimus with increased MMF dosage is recommended by the Journal of Hepatology 8, 9
Potential conversion from tacrolimus to an mTOR inhibitor (sirolimus/everolimus) can be considered if renal function is stable (eGFR >40 ml/min/1.73m²) and proteinuria is <500 mg/g creatinine, according to Kidney International and Journal of Hepatology 2, 3

Measuring proteinuria monthly for the first 3 months after intervention is suggested by Kidney International 2
Checking serum creatinine and tacrolimus levels weekly initially, then every 2 weeks for 2 months is recommended by Kidney International and Praxis Medical Insights 2, 4
Repeating kidney biopsy if proteinuria worsens or renal function deteriorates despite therapy is advised by Kidney International and American Journal of Transplantation 2, 6

Tacrolimus-induced nephrotoxicity has both reversible (vasoconstriction) and potentially irreversible (chronic fibrosis) components, according to the Journal of Hepatology 3
MMF in combination with CNI reduction (at least 50%) is associated with significant improvement in renal function with low risk of acute rejection, as reported by the Journal of Hepatology 3

Excessive reduction of immunosuppression may increase risk of rejection, according to the Journal of Hepatology 3
Converting to mTOR inhibitors when proteinuria is already significant (>500 mg/g creatinine) may worsen the proteinuria, as suggested by Gut 7
Tacrolimus levels should be monitored closely when adding medications that affect CYP3A4 metabolism, as recommended by Praxis Medical Insights 4, 5
Complete withdrawal of CNIs carries a high risk of acute rejection (3-30%) and should be avoided, according to the Journal of Hepatology 3